European Union's human medicines committee (CHMP) said on Friday it is not updating its opinion on Eisai and Biogen's ...

The European Union's drugs regulator said on Friday it concluded a review into the safety of Eisai and Biogen's Alzheimer's ...

India's largest drugmaker by revenue Sun Pharmaceutical is aiming to launch its experimental anti-obesity and type 2 diabetes ...

Higher fish consumption was tied to less disability progression among people with multiple sclerosis (MS), a case-control ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi.

Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...

Shares of Biogen Inc. BIIB slipped 2.07% to $140.49 Wednesday, on what proved to be an all-around mixed trading session for ...

Health updates cover U.S. involvement in WHO meetings, UK approval of Moderna's RSV vaccine, a Texas measles outbreak, FDA ...

We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to take a look at where Biogen Inc.

As one study finds, traditional titles are leading enterprise Gen AI adoption and the Chief AI Officer role continues to grow ...

Biogen Inc. (BIIB), based in Cambridge, Massachusetts, is a leading biotechnology company focused on developing and delivering innovative therapies for neurological and neurodegenerative diseases.

Allworth Financial LP lowered its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 53.6% during the fourth quarter, Holdings Channel reports. The firm owned 548 shares of the ...